Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function
Authors:
Open Access
- 5 May 2015
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10034
Abstract
A total of 142 premenopausal women with symptomatic adenomyosis underwent ultrasound (US)-guided percutaneous microwave ablation (PMWA) at the Chinese PLA General Hospital. This study aimed to evaluate changes in serum pituitary, gonadal hormone and cancer antigen 125 (CA125) levels after US-guided PMWA. Therefore, estradiol (E2), follicle-stimulating hormone (FSH), prolactin (PRL) and CA125 levels were evaluated before ablation and at 3, 6, 9 and 12 months after ablation. No significant differences were observed in the E2 and FSH levels pre-ablation and during follow-up (E2: p = 0.933, p = 0.987, p = 0.106, p = 0.936; FSH: p = 0.552, p = 0.295, p = 0.414, p = 0.760). The mean absolute values of serum CA125 and PRL were significantly decreased at 3, 6, 9 and 12 months after ablation (CA125: p < 0.001, p < 0.001, p < 0.001, p = 0.003; PRL: p < 0.001, p < 0.001, p < 0.001, p < 0.001). A significant correlation between changes in CA125 levels and uterine volume was found (p < 0.001). No evidence of a decline in ovarian function was observed after US-guided PMWA.Keywords
This publication has 26 references indexed in Scilit:
- Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomesHuman Reproduction Update, 2012
- Ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroid treatment – A clinical studyInternational Journal of Hyperthermia, 2011
- Adenomyosis: Review of the LiteratureJournal of Minimally Invasive Gynecology, 2011
- The Role of Prolactin– and Endometriosis-Associated InfertilityObstetrical & Gynecological Survey, 2009
- The menopausal transitionFertility and Sterility, 2008
- What Can We Learn from Rodents about Prolactin in Humans?Endocrine Reviews, 2007
- New interventional techniques for adenomyosisBest Practice & Research Clinical Obstetrics & Gynaecology, 2006
- Anti‐müllerian hormone as a marker of ovarian reserve*Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005
- Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transitionMenopause, 2004
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983